CME director sells 4,200 shares at $309.65

CME Group Inc. director Bryan T. Durkin reported an open-market sale of Class A common stock.

Rhea-AI Filing Summary

CME Group Inc. director Bryan T. Durkin reported an open-market sale of Class A common stock. On February 23, 2026, he sold 4,200 shares at a weighted average price of $309.65 per share, within a price range of $309.25 to $310.07. After this transaction, he directly holds 43,007 shares of CME Group Class A common stock.

Insider Trade Summary

Net Seller: 4,200 shares

Net Sell 1 txn

Insider Durkin Bryan T

Role Director

Sold 4,200 shs ($1.30M)

Type	Security	Shares	Price	Value
Sale	Common Stock Class A	4,200	$309.65	$1.30M

Holdings After Transaction: Common Stock Class A — 43,007 shares (Direct)

Footnotes (1)

1. F1. On February 23, 2026, Mr. Durkin sold an aggregate of 4,200 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $309.25 to $310.07. The Company maintains a record of the transaction and copies will be provided upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CME (CME) director Bryan T. Durkin report in this Form 4?

Bryan T. Durkin reported selling 4,200 shares of CME Group Class A common stock. The sale was an open-market transaction on February 23, 2026, at a weighted average price of $309.65 per share, with prices ranging from $309.25 to $310.07.

How many CME (CME) shares did Bryan T. Durkin sell and at what price?

He sold 4,200 shares of CME Group Class A common stock. The weighted average sale price was $309.65 per share, with individual trades executed between $309.25 and $310.07, as disclosed in the aggregated pricing footnote.

What is Bryan T. Durkin’s remaining CME (CME) share ownership after this transaction?

Following the reported sale, Bryan T. Durkin directly owns 43,007 shares of CME Group Class A common stock. This figure reflects his direct holdings immediately after completing the 4,200-share open-market sale on February 23, 2026.

Was the CME (CME) insider transaction an open-market sale?

Yes, the filing describes the transaction as an open-market sale. The Form 4 uses transaction code “S” and explicitly labels the action as an open-market sale of CME Group Class A common stock on February 23, 2026.

How were the sale prices for Bryan T. Durkin’s CME (CME) trades reported?

The individual trade prices were aggregated into a weighted average within a $1 range. The reported average sale price was $309.65, with underlying transactions executed between $309.25 and $310.07, and detailed records are available from the company upon request.

Does the CME (CME) Form 4 mention any indirect ownership or special entities?

No, this Form 4 indicates direct ownership with code “D” and no special nature-of-ownership description. The footnote focuses on aggregated pricing and trade ranges, not on trusts, partnerships, or other entities holding the shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:46 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Durkin Bryan T

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	02/23/2026	02/23/2026	S		4,200	D	$309.65(1)	43,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On February 23, 2026, Mr. Durkin sold an aggregate of 4,200 shares of CME Group Class A common stock. For reporting purposes, the sale prices within $1 range have been aggregated and the weighted average has been reported. The price range was $309.25 to $310.07. The Company maintains a record of the transaction and copies will be provided upon request.

Remarks:

	By: Margaret Austin Wright For: Bryan T. Durkin	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.